Myriad outlines $770M-$790M 2026 revenue and 66%-67% gross margin ranges while suspending adjusted EBITDA guidance

EarningsNegative

AI Analysis

Myriad Genetics provided 2026 revenue guidance of $770M-$790M with gross margins of 66%-67%, while suspending adjusted EBITDA guidance.

Revenue

$770M-$790M

Guidance

2026 revenue guidance of $770M-$790M with 66%-67% gross margin; adjusted EBITDA guidance suspended

Importance:5/10

Sentiment:

-0.30

guidancerevenuegross marginEBITDA suspension

Related Companies

Read the original article

Published by Seeking Alpha Healthcare on July 31, 2026 5:34 AM